The efficacy of intravitreal injection of Ranibizumab before vitrectomy in the treatment of proliferative diabetic retinopathy

Abstract

Objective To evaluate the efficacy of intravitreal Ranibizumab injection before vitrectomy in the treatment of proliferative diabetic retinopathy (PDR) . Methods The data of 128 eyes of 92 patients of PDR from Jan. 2016 to Dec. 2016 were enrolled and analyzed retrospectively. All patients were randomly divided into observation group, 66 eyes of 46 patients, and control group, 62 eyes of 46 patients. The control group was treated with vitrectomy only. The observation group received intravitreal Ranibizumab injection before vitrectomy. The efficacy of two groups were compared. Results The operation time and hospital stay time in observation group were shorter than those in control group (P=0.000). At 3 months after operation, the visual acuity improvement rate was 92.42% in the observation group and 80.65% in the control group (P=0.034). The average postoperative visual acuity in the observation group was higher than that in the control group (P=0.009) . The intraocular pressure in the observation group was lower than that in the control group (P=0.001), the central macular retinal thickness in the observation group was thinner than that of the control group (P=0.000). The complication rate in the observation group was 3.03%, which was lower than 14.25% in the control group (P=0.020). The postoperative vascular endothelial growth factor (VEGF) and pigment epithelium derived factor (PEDF) in the observation group were lower than those in the control group (P=0.001, 0.000). Conclusion Intravitreal injection of Ranibizumab before vitrectomy for the treatment of PDR can promote visual acuity and improve the high level of VEGF and PEDF after operation. Key words: Retinopathy, diabetic, proliferative; Ranibizumab, intravitreal injection; Vitrectomy; Efficacy